Candida rugosa , an Emerging Fungal Pathogen with Resistance to Azoles: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program
- 1 October 2006
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 44 (10) , 3578-3582
- https://doi.org/10.1128/jcm.00863-06
Abstract
Candida rugosa is a fungus that appears to be emerging as a cause of infection in some geographic regions. We utilized the extensive database of the ARTEMIS DISK Antifungal Surveillance Program to describe the geographic and temporal trends in the isolation of C. rugosa from clinical specimens and the in vitro susceptibilities of 452 isolates to fluconazole and voriconazole. C. rugosa accounted for 0.4% of 134,715 isolates of Candida , and the frequency of isolation increased from 0.03% to 0.4% over the 6.5-year study period (1997 to 2003). C. rugosa was most common in the Latin American region (2.7% versus 0.1 to 0.4%). Decreased susceptibility to fluconazole (40.5% susceptible) was observed in all geographic regions; however, isolates from Europe and North America were much more susceptible (97 to 100%) to voriconazole than those from other geographic regions (55.8 to 58.8%). C. rugosa was most often isolated from blood and urine in patients hospitalized at the Medical and Surgical inpatient services. Notably, bloodstream isolates were the least susceptible to both fluconazole and voriconazole. C. rugosa should be considered, along with the established pathogens Candida krusei and Candida glabrata , as a species of Candida with reduced susceptibility to the azole antifungal agents.Keywords
This publication has 19 references indexed in Scilit:
- Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility TestingClinical Microbiology Reviews, 2006
- Current Treatment Strategies for Disseminated CandidiasisClinical Infectious Diseases, 2006
- Relationship between MIC and Minimum Sterol 14α-Demethylation-Inhibitory Concentration as a Factor in Evaluating Activities of Azoles against Various Fungal SpeciesJournal of Clinical Microbiology, 2005
- Comparison of Results of Voriconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance ProgramJournal of Clinical Microbiology, 2005
- Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyondCandida albicansandAspergillus fumigatusJournal of Clinical Microbiology, 2004
- Comparison of Results of Fluconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance ProgramJournal of Clinical Microbiology, 2004
- Guidelines for Treatment of CandidiasisClinical Infectious Diseases, 2004
- Comparison of the Susceptibilities of Candida spp. to Fluconazole and Voriconazole in a 4-Year Global Evaluation Using Disk DiffusionJournal of Clinical Microbiology, 2003
- Has Antifungal Susceptibility Testing Come of Age?Clinical Infectious Diseases, 2002
- Fungemia and Colonization with Nystatin-Resistant Candida rugosa in a Burn UnitClinical Infectious Diseases, 1994